2 results
Approved WMOWill not start
Primary objectiveTo assess the efficacy of tildrakizumab treatment (as assessed by PASI 75) in moderate-to-severe plaque psoriasis patients who are non-responders to DMF. Secondary objectivesTildrakizumab- To assess the efficacy of tildrakizumab…
Approved WMORecruiting
Primary objectives• To evaluate complement activation after topical imiquimod challenge• To evaluate complement activation after local UV-B challenge